1 – 10 of 51
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Next-generation CD40 agonists for cancer immunotherapy
(
- Contribution to journal › Scientific review
-
Mark
Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes
(
- Contribution to journal › Article
-
Mark
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1) : a single-arm, multicentre phase 1b/2 study
(
- Contribution to journal › Article
- 2023
-
Mark
Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
(
- Contribution to journal › Article
-
Mark
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
(
- Contribution to journal › Article
-
Mark
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
(
- Contribution to journal › Article
- 2022
-
Mark
Transcriptional profiling demonstrates altered characteristics of CD8 + cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
(
- Contribution to journal › Article
- 2021
-
Mark
Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
(
- Contribution to journal › Scientific review
-
Mark
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
(
- Contribution to journal › Article